ETON Eton Pharmaceuticals, Inc. logo

ETON Eton Pharmaceuticals, Inc.

Healthcare
$32.59-6.89%ClosedMarket Cap: $892.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

29.05

P/S

10.27

EV/EBITDA

155.37

DCF Value

$-41.59

FCF Yield

1.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

54.8%

Operating Margin

2.3%

Net Margin

-1.7%

ROE

-5.7%

ROA

-1.5%

ROIC

3.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$24.3M$1.6M$
Q4 null$21.3M$1.5M$
FY null$80.0M$-4.6M$
Q3 null$22.5M$-1.9M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$57.00

Target (Median)

$57.00

Target Range

$57.00 - $57.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-15
Craig-HallumBuy
2026-03-20
B. Riley SecuritiesBuy
2026-03-20
HC Wainwright & Co.Buy
2026-03-20
HC Wainwright & Co.Buy
2025-05-29

Trading Activity

Insider Trades

View All
RIEDEL NORBERT Gdirector
SellWed Apr 22
RIEDEL NORBERT Gdirector
SellWed Apr 22
RIEDEL NORBERT Gdirector
SellThu Feb 05
RIEDEL NORBERT Gdirector
SellWed Jan 14
RIEDEL NORBERT Gdirector
SellWed Jan 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.82

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Peers